Pharmaceuticals

Synthetic Lethality: Q&A with Oren Gilad, CEO of Aprea Therapeutics

bexib
By bexib 0 Min Read

Gilad discusses how this method could be used to treat a variety of cancers without exposing patients to the side effects of chemotherapy.

You Might Also Like

FDA Grants Fast Track Designation to Sumitomo Pharmaceuticals’ Novel Treatment for Patients with Relapsed or Refractory Acute Myeloid Leukemia

MIT study reveals how certain cells become vulnerable and resilient in AD

Resolution Presents Liver Disease Treatment Data at EASL 2024

Scemblix Demonstrates Major Molecular Response Improvements in Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Regeneron’s Global Program Head for Rimbosertamab Discusses Rimbosertamab’s Potential as a First-Line Treatment for Multiple Myeloma

Share This Article
Previous Article Bitcoin’s role as collateral in real estate development financing
Next Article GLP-1 Therapy Significantly Increases Visceral Adipose Tissue Metabolic Activity in Patients with Obesity, Obstructive Sleep Apnea
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

In preparation. Introducing a week-long culinary collaboration to raise money for children’s food education
Hospitality & Tourism
Listen: Top 3 Bank Automation News Podcasts of 2024
Banking
What is precision agriculture and how does it work?
Agro Businesses
Opening Facebook shop in 2025
Retail & E-commerce